About Precipio Diagnostics
Precipio Diagnostics is a company based in New Haven (United States) founded in 1997. The company has 60 employees as of December 31, 2024. Precipio Diagnostics offers products and services including Molecular Kits, IV-Cell Culture Media, and Hematopathology Services. Precipio Diagnostics operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
- Headquarter New Haven, United States
- Employees 60 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Precipio, Inc.
-
Annual Revenue
$18.53 M (USD)21.95as on Dec 31, 2024
-
Net Profit
-$4.29 M (USD)26.7as on Dec 31, 2024
-
EBITDA
-$2.7 M (USD)55.71as on Dec 31, 2024
-
Latest Funding Round
$810.84 K (USD), Post-IPO
Oct 31, 2017
-
Investors
Enhanced Capital
& 3 more
-
Employee Count
60
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Precipio Diagnostics
Precipio Diagnostics is a publicly listed company on the NASDAQ with ticker symbol PRPO in USA, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Precipio Diagnostics
Precipio Diagnostics offers a comprehensive portfolio of products and services, including Molecular Kits, IV-Cell Culture Media, and Hematopathology Services.
Kits for detecting driver mutations in blood cancers
Media for multi-cell lineage culturing in diagnostics
Diagnostic testing for accurate blood cancer analysis
People of Precipio Diagnostics
Unlock access to complete
Unlock access to complete
Funding Insights of Precipio Diagnostics
Investors in Precipio Diagnostics
Precipio Diagnostics has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Enhanced Capital, Connecticut Innovations and Ironwood Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital services for biotech, IT, and innovative sectors in Connecticut.
|
Locked | Locked | Locked | |
|
Private equity and debt investments are focused on multiple sectors.
|
Locked | Locked | Locked | |
|
A capital access and managed service platform is provided.
|
Locked | Locked | Locked |
Investor details for Precipio Diagnostics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Precipio Diagnostics
Investment portfolio details for Precipio Diagnostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Precipio Diagnostics
Detailed financials for Precipio Diagnostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Precipio Diagnostics Comparisons
Peer comparison for Precipio Diagnostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Precipio Diagnostics
Precipio Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
|
| Locked | Locked | Locked |
Diagnostic services are provided through laboratories and radiology units.
|
Detailed competitors of Precipio Diagnostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Precipio Diagnostics
Complete news archive for Precipio Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Precipio Diagnostics
Precipio Diagnostics was founded in 1997 and raised its 1st funding round 14 years after it was founded.
Precipio Diagnostics is headquartered in New Haven, United States. It is registered at New Haven, Connecticut, United States.
As of Dec 31, 2024, the latest employee count at Precipio Diagnostics is 60.
Annual revenue of Precipio Diagnostics is $18.53M as on Dec 31, 2024.
Provider of cancer diagnostics and second opinion tools. The company uses ICE COLD-PCR technology to detect cancer mutations. The product includes SmartGen is a combination of diagnostic tools for the prognosis and diagnosis of cancer. SmartPath is a service that couples the patient and treating physician, with an academic expert for a second opinion. Results are generally provided within hours and customers can also request a live consultation with the pathologist. It also provides a HemeScreen Panel for screening hematologic malignancy.
Precipio Diagnostics's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
Precipio Diagnostics offers Molecular Kits, IV-Cell Culture Media, and Hematopathology Services.
Yes, Precipio Diagnostics is publicly traded on NASDAQ under the ticker symbol PRPO.
Precipio Diagnostics has 4 investors. Key investors include Enhanced Capital, Connecticut Innovations, Ironwood Capital, and Kuzari.
The ticker symbol of Precipio Diagnostics is PRPO on NASDAQ.